CAJ | 학술논문

Bcl-2蛋白小分子抑制剂是以Bcl-2家族抗凋亡蛋白为靶点的新型抗肿瘤药物.近年来,ABT-737、ABT-263、棉酚、apogossypol、TW-37、obatoclax、HA14-1等Bcl-2小分子抑制剂已成为研究的热点,临床前试验表明该类药物单药对某些肿瘤有效,与放化疗联合使用具有明显的协同效果.
Bcl-2단백소분자억제제시이Bcl-2가족항조망단백위파점적신형항종류약물.근년래,ABT-737、ABT-263、면분、apogossypol、TW-37、obatoclax、HA14-1등Bcl-2소분자억제제이성위연구적열점,림상전시험표명해류약물단약대모사종류유효,여방화료연합사용구유명현적협동효과.
Small molecule inhibitors of Bcl-2 are a novel class of anticancer drugs that target anti-apoptotic proteins. In recent years,small molecule inhibitors such as ABT-737 ,ABT-263, gossypol, apogossypol,TW-37,obatoclax, HAl4-1 have attracted much reseach attention. Preclinical trials have shown that the inhibitors have cancer killing effect on some tumors when used alone and exhibit striking synergistic effect when combined with radiotherapy and/or chemotherapy.